APA (7th ed.) Citation

Rusakiewicz, S., & Halama, N. (2017). NKp30 isoforms and NKp30 ligands are predictive biomarkers of response to imatinib mesylate in metastatic GIST patients. OncoImmunology, 6(1), . https://doi.org/10.1080/2162402X.2015.1137418

Chicago Style (17th ed.) Citation

Rusakiewicz, Sylvie, and Niels Halama. "NKp30 Isoforms and NKp30 Ligands Are Predictive Biomarkers of Response to Imatinib Mesylate in Metastatic GIST Patients." OncoImmunology 6, no. 1 (2017). https://doi.org/10.1080/2162402X.2015.1137418.

MLA (9th ed.) Citation

Rusakiewicz, Sylvie, and Niels Halama. "NKp30 Isoforms and NKp30 Ligands Are Predictive Biomarkers of Response to Imatinib Mesylate in Metastatic GIST Patients." OncoImmunology, vol. 6, no. 1, 2017, https://doi.org/10.1080/2162402X.2015.1137418.

Warning: These citations may not always be 100% accurate.